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RESUMEN 
Objetivos: El efecto anticoagulante y la citotoxicidad de una fracción de polisacáridos de alto peso mo-
lecular (1000RS), obtenida de la túnica de la ascidia Microcosmus exasperatus, fueron evaluados. 
Métodos: La actividad anticoagulante de 1000RS fue evaluada mediante los ensayos de tiempo de trom-
boplastina parcial activado (TTPa), tiempo de trombina (TT), tiempo de protrombina (TP), anti factor 
Xa y anticoagulante lúpico (dRVVT). La citotoxicidad sobre las células hematopoyéticas murinas fue 
evaluada usando el método del MTT. 
Resultados: Esta fracción rica en galactosa mostró ser un anticoagulante potencial debido a su efecto 
inhibidor de la vía intrínseca de la coagulación. Así mismo, las dosis anticoagulantes de esta fracción no 
afectan la viabilidad celular, lo cual ratifica su potencial como agente terapéutico. 
Conclusión: El efecto anticoagulante in vitro de 1000RS ocurre a dosis inocuas, sin embargo, éste debe ser 
evaluado en modelos in vivo, así como su citotoxicidad sobre células humanas normales. 
Palabras claves: Anticoagulantes, ascidia, Microcosmus exasperatus, polisacáridos. 
ABSTRACT 
Aims: The anticoagulant effect and cytotoxicity of a high molecular weight polysaccharide fraction 
(1000RS) obtained from the tunic of the ascidia Microcosmus exasperatus were evaluated.
Methods: Anticoagulant properties of 1000RS was evaluated by activated Partial Thromboplastin Time 
(aPTT), Thrombin Time (TT), Prothrombin Time (PT), anti-factor Xa and lupic anticoagulant (dRVVT) 
assays. Cytotoxicity was tested on murine hematopoietic cells using MTT assay. 
Results: This galactose rich fraction showed to be a potential anticoagulant due to its inhibitory effect on 
the intrinsic coagulation pathway. At the same time, anticoagulant doses of this fraction have no effect 
on cellular viability, which means that it can be used as a therapeutic agent. 
Conclusion: In vitro anticoagulant effect of 1000RS occurs at innocuous doses, however, it still need to be 
tested using in vivo models and its cytotoxicity evaluated in normal human cell lines.
Keywords: anticoagulants, ascidian, Microcosmus exasperatus, polysaccharides.
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INTRODUCTION 
Sulfated polysaccharides from marine sources are current-
ly being investigated as therapeutics in a wide range of 
diseases. Several reports on marine natural products have 
described anticoagulant and non-anticoagulant effects of 
novel molecules without the undesirable side effects of 
heparin, which interacts with distinct plasma proteins1,2. 
Both positive and negative effects of heparin are related to 
its unique structural features such as heterogeneity of in-
tra-chain domains and its highly negative charge and selec-
tive sulfation3.  Recent studies have revealed other poten-
tial therapeutic effects of complex carbohydrates on many 
biological models of inflammation, cancer, metastasis, viral 
infection, atherosclerosis and acute tissue injury4,5.
Diverse structural features such as sugar composition, type 
of linkage, molecular weight (Mw), distribution and charge 
density allow polysaccharides from different sources to in-
teract with a wide variety of molecules involved in biolog-
ical processes3,5. For instance, the study of lacquer polysac-
charides indicated that carboxyl and sulfate groups have 
a synergistic anticoagulant action; the presence of 6-O-SO3 
in the side chains is a key feature for this activity while 
sulfation at 2-position has not such effect. Sulfation of algi-
nate, a polymer of (1 → 4) linked β-D-mannuronic acid and 
α-L-guluronic acid that naturally contain carboxyl groups, 
increases its anticoagulant properties, at the same time, 
position of carboxyl groups may also have impact on this 
bioactivity2. The fucoidan obtained from Fucus vesiculosus 
displays procoagulant effect when it presents a minimal de-
gree of sulfation of 0.5 and a chain of at least 70 sugar units6.
The tunic and organs of different ascidians have been 
studied as a source of new bioactive natural products7–10. 
Among those compounds, polysaccharides like L-galactans 
have shown to be the main constituent of this filter feeding 
marine invertebrate tunic[11,12]. These carbohydrates present 
different size and structure and they likely have distinct 
biological effects; for instance tunic of Herdmania monus is 
mainly composed by a 3-O-sulfated 4-linked α-L-galactan, 
the galactan from Styela plicata is also substituted by sugar 
residues at 2-position and Ciona intestinalis possess a poorly 
sulfated and highly branched α-L-galactan11–13. 
Here, we aimed to evaluate anticoagulant and cytotoxic 
effects of a galactose-rich polysaccharide fraction obtained 
from the tunic of Microcosmus exasperatus. Data obtained 
revealed a mechanism of coagulation different from hepa-
rin-like anticoagulants at innocuous doses. 
MATERIAL AND METHODS 
Biological material 
The ascidia Microcosmus exasperatus was collected at Gua-
nabara Bay, Rio de Janeiro, Brazil. Tunics were separated 
from the internal organs and cleaned, depigmented and 
freeze-dried before extraction.  
Extraction of the polysaccharides from the tunic
The defatted and dried tunics (64.9 g) of M. exasperatus 
were extracted by three successive proteolytic digestions in 
a 0.1 M sodium acetate buffer containing 5 mM EDTA, 5 
mM cysteine and papain (10%); each enzymatic digestion 
was incubated for 24 h at 60 °C14. Supernatants of the three 
digestions were collected and polysaccharides present in 
this final solution were precipitated by the exhaustive ad-
dition of ethanol and kept at 4 °C for 24 h. Finally, the crude 
precipitate of polysaccharides was obtained by centrifuga-
tion (4500 rpm for 10 min at 15 °C), dialyzed using a 1 kDa 
MWCO dialysis tube and freeze-dried. 
Fractionation of the crude precipitated of polysaccha-
rides 
The isolated extract (4.1 g) was dialyzed with deionized 
water by using a 1000 kDa molecular weight cut-off mem-
brane; retained and eluted fractions were collected, evap-
orated and freeze-dried. The retained fraction was subse-
quently solubilized and submitted to freezing–thawing 
cycles until precipitation stopped; supernatants were sep-
arated from precipitates through centrifugation for 10 min 
at 10 °C. 
The presence of negative charges in the carbohydrates, 
which could be assigned to sulfate groups, was tested 
through the complex formed between sulfated polysaccha-
rides and dimethylmethylene blue (DMB). 
Glycosyl composition analysis
1000RS fraction (2.0 mg) was hydrolyzed with 2.0 M trif-
luoroacetic acid (TFA) for 8 h at 100 °C. The obtained hy-
drolyzate was reduced (18 h) and acetylated (12 h) by using 
NaBH4 (pH 9.0) and acetic anhydride:pyridine (1:1, v/v) 
at room temperature, respectively. Alditol acetates were 
separated by GC–MS (Varian Saturn 2000R-3800) using a 
DB-225 column (30 m × 0.25 mm i.d) and identified by com-
paring their retention time and mass fragmentation pattern 
with the alditol acetates of standard monosaccharides15. 
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Blood clotting assays
Anticoagulant activity of the fraction 1000RS at differ-
ent concentrations (11.9-44.8 µg/mL) was determined by 
measuring the clotting time (in seconds) of unfrozen hu-
man platelet-poor plasma using an ACL ELITE PRO coagu-
lometer at 37 °C. The activated partial thromboplastin time 
(aPTT), prothrombin time (PT), thrombin time (TT), anti-Xa 
factor and a dilute Russell’s Viper Venom time-based as-
say (Lupus anticoagulant-dRVVT) reagents were prepared 
and used according to the manufacturer’s (HemosIL®, In-
strumentation Laboratory) instructions. Clot formation in 
PT, TT, aPTT and dRVVT assays was measured at 660 nm 
and calcium chloride was added to trigger coagulation re-
actions in aPTT assay. Unfractionated heparin (200.47 IU/
mg; 6th International Standard) was used as positive con-
trol. Results were expressed as the mean of the response ± 
standard deviation (SD). 
Chromogenic assay (anti-Xa factor) was made by incubat-
ing (30 s) 1000RS with plasma, Chromogenic substrate (an-
FXasub, 15 s) and Factor Xa reagent (anFxaRgt, 90 s). The 
concentration of residual Factor Xa was measured (60 s) by 
detection of paranitroaniline at 405 nm. 
Cellular viability of hematopoietic cells from C57BL/6 
mice (MTT assay)
Hematopoietic cells were obtained from the bone marrow 
of femurs and tibias of six male and female between 4 and 6 
months C57BL/6 mice.  After collecting bone marrow, cells 
were treated with ACK (Ammonium-Chloride-Potassium) 
solution to eliminate red cells and then incubated overnight 
in a flask with RPMI medium containing 10% (v/v) fetal 
bovine serum. Afterwards, only non-adherent cells that 
correspond to hematopoietic cells were collected and used 
subsequently. Experiments were done in 96-well plates 
with 5 x 105 cells/well (100 µL) and three different concen-
trations (0.5, 0.25 and 0.0078 mg/mL) of 1000RS and hep-
arin were used for 24 h of culture. After this period, cells 
were incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyl-2H-tetrazoliumbromide (MTT) aqueous solution 
(5 mg/mL, 20 µL/well) for 2 h, centrifuged at 200 g for 8 
min and the supernatant solution was discarded. Formazan 
crystals were dissolved with a solution (200 µL) containing 
triton-X, HCl and isopropyl alcohol. Finally, the absorbance 
was measured at 560 nm in a plate reader. Cell viability 
was expressed as the percentage of viable cells normalized 
using control cells. Results are expressed as mean values 
and standard deviation (SD) of six different experiments in 
triplicate16.
All protocols used for the animal experiments were ap-
proved by the Animal Ethics committee of the Hospital 
Naval Marcílio Dias, Rio de Janeiro (Law n° 11.794 of 8 Oc-
tober 2008, Legislative Decree n° 6.899 of 15 July 2009).
RESULTS 
1000RS represents a yield of 5.3% of the crude extract of 
polysaccharide obtained from M. exasperatus. It was a frac-
tion mainly composed by galactose (>90%), while other 
monomers like arabinose, xylose, mannose and glucose 
are present in minor proportion. A solution of this fraction 
formed a complex with the cationic dye DMB and the in-
tense coloration suggests that this fraction possess nega-
tively charged polysaccharides. 
To evaluate how this fraction affects the secondary hemo-
stasis, aPTT, TT and PT assays (Table 1) were performed in 
vitro. 
Table 1. Anticoagulant activity of the 1000RS fraction (Fig.1)
Sample
Amount 
(µg/mL)
Clotting time (s)
aPTT TT PT
Control 0.0 26.7 ± 0.0 15.9 ± 0.0 13.9 ± 0.0
Heparin
1.9 86.8 ±  6.4 169.5 ± 0.2 15.5 ± 0.3
2.8 163.7 ± 21.7 169.5 ± 0.3 16.9 ± 0.4
3.7 247 ± 0.0 169.5 ± 0.4 18.4 ± 0.6
1000RS
11.9 53.4 ± 1.0 16.3 ± 0.1 13.9 ± 0.2
23.3 72.3 ± 1.8 16.1 ± 0.2 15.1 ± 0.5
34.2 96.0 ± 4.0 19.4 ± 0.2 15.4 ± 0.1
44.8 129.0 ± 9.5 21.9 ± 0.8 16.4 ± 0.2
Clotting time (n=3) are expressed (in seconds) as the mean  
± SD.
1000RS prolonged the aPTT in a dose dependent manner, 
whereas the TT and PT were poorly affected by the differ-
ent concentrations of 1000RS (Fig.1).
This fraction did not prolong the prothrombin and throm-
bin, suggesting that the inhibition of the coagulation may 
be due to an interaction with different coagulation factors 
such as factor X, V and II of the common pathway. For 
this reason the effect of 1000RS on factor X was evaluat-
ed through the anti-Xa assay. At the same time, to better 
understand how this fraction interferes with the thrombus 
formation, the lupus anticoagulant assay was also carried 
out (Table 2).
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Figure 1. Anticoagulant activity of heparin (▲) and 1000RS 
fraction (○): A) aPTT, B) PT, C) TT.  The highest reference 
time is 247.5 seconds for PTT, 165 for PT and 169.5 for TT. 
Standard curves (n=3) were analyzed by linear regression 
statistics and the coefficients of determination (r) were ob-
tained for all of them; heparin curves: 0.97 (aPTT), 0.98 (PT), 
0.72 (TT) and 1000RS curves: 0.99 (aPTT), 0.96 (PT), 0.89 (TT).
Table 2.  Anti-Xa and Lupus anticoagulant assay of 1000RS 
fraction.
Sample
Amount 
(µg/mL)
dRVVT (s) 
Anti-Xa factor 
(UI/mL)a 
Control   0.0 30.1 ± 0.0 0.05 ± 0.01
1000RS
11.9 26.6 ± 0.3 0.02 ± 0.02
23.3 26.1 ± 0.0 0.00 ± 0.01
34.2 25.2 ± 0.2 0.00 ± 0.01
44.8 27.3 ± 0.8 0.00 ± 0.03
dRVVT and anti-Xa values are represented as the mean of 
the values ± SD of n=3 independent experiments. aValues less 
than or equal to -0.2 UI/mL are undetectable, they are consid-
ered to be 0.00 UI/mL.
The anticoagulant activity of 1000RS is not due to the in-
hibition of the factor X, since the amount of residual Xa at 
different concentrations of the fraction was lower than the 
control (Table 2). At the same time, the activity of 1000RS 
as a lupus anticoagulant was evaluated using the diluted 
Russell’s Viper Venom test (dRVVT); this fraction did not 
impair the activation of factor X by an enzyme present in 
the viper venom.
Furthermore, as the ascidian polysaccharide fraction 
showed to be a potential anticoagulant fraction with prob-
ably less adverse effects than heparin or other known an-
ticoagulants, it is important to determine if this fraction 
contains carbohydrates that could be cytotoxic at the anti-
coagulant doses. For this purpose, in vitro cell viability was 
evaluated with the MTT assay using hematopoietic cells 
obtained from C57BL/6 mice (Fig. 2)17. 
Figure 2. Cellular viability of murine hematopoietic cells 
after treatment with the 1000RS (○) and Heparin (□) at 
different concentrations. Data are shown as mean of the 
% viability ± SD of at least n=6 independent experiments 
performed in triplicate. 
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After treatment of cells with 1000RS and heparin, the vi-
ability observed has not significantly changed and some-
times it was even higher than the control (set as 100% of 
viable cells). These results indicate that polysaccharides 
that constitutes 1000RS fraction are potential anticoagulant 
agents with non-cytotoxic effect at least at doses used here. 
DISCUSSION
Previous reports on the polysaccharide composition of as-
cidian tunics had demonstrated that this tissue is mainly 
constituted by a high molecular weight galactan, which 
have different sulfation pattern according to the specie 
of tunicate11,18. This new fraction from M. exasperatus also 
showed the presence of polysaccharides that are mainly 
constituted by galactose residues, which may be negatively 
charged along the chain. Additionally, this fraction was re-
tained by the 1000 kDa MWCO membrane, which supports 
the existence of high molecular weight polysaccharides in 
this ascidian. 
Plasma proteases that are required for clot generation are 
common targets of several anticoagulants. Although those 
substances can effectively avoid thrombus formation and 
growth, their use represents a significant risk of excessive 
bleeding and hemostatic disorders19. Considering that sul-
fated polysaccharides have frequently been shown as anti-
coagulant substances, we hypothesized that 1000RS could 
be a potential inhibitor of the coagulation process20,21.  
1000RS can significantly inhibit the intrinsic coagulation 
pathway, but neither the extrinsic pathway nor the throm-
bin-mediated fibrin formation are affected by this polysac-
charide fraction22. Thus, it does not alter the coagulation 
process by interacting with factor VII or factor II (prothrom-
bin) of the extrinsic and common coagulation pathways, re-
spectively23. Additionally, the poor effect on thrombin and 
prothrombin time suggests that the extent of fibrinogen is 
normal and remains unaffected in the presence of this frac-
tion, resulting in normal fibrin formation. Also, the lack of 
inhibitory activity on thrombin indicates that thrombin-in-
duced activation of factor V, factor VIII and platelets, essen-
tial components of blood coagulation, remains unaltered24.
The aPTT prolongation by 1000RS was 22.2-fold lower than 
heparin; the clotting time increases, in average, 2.36 s (r= 
0.9619) and 59.36 s (r= 0.9830) after the treatment at differ-
ent concentrations of the polysaccharide fraction and hep-
arin, respectively.  Although heparin is more potent, this 
result showed that 1000RS has anticoagulant activity and 
probably inhibits clot formation through the interaction 
with one or more key intrinsic pathway clotting factors. 
Heparin acts by blocking activated factor X (factor Xa)23,24.
The amount of residual factor Xa after treatment with this 
fraction was lower than control at the different concentra-
tions tested25, which means that it does not bind to the ac-
tive site of activated Factor X (FXa) and allows the interac-
tion between FXa and its substrate. Therefore the thrombin 
generation can be normally achieved26. Furthermore, an en-
zyme present in the viper venom did not activate factor X 
in the presence of 1000RS fraction; with this activated factor 
in the presence of factor V and phospholipid, prothrombin 
is converted to thrombin27–29. Hence, it does not decrease 
the availability of phospholipids to support this reaction 
and the clot is formed at all the concentrations tested. The 
fact that this fraction does not act as a lupus anticoagulant, 
along with the negative effect on factor X and thrombin 
time, confirmed that it is not an inhibitor of the common 
coagulation pathway. This indicates that the anticoagulant 
effect is mainly due to the inhibition of an intrinsic coagu-
lation factor such as prekallikrein, high molecular weight 
kininogen, XII, XI, IX and VIII factors23,29. Consequently, it 
can be assumed that 1000RS does not behave as a hepa-
rin-like anticoagulant, being a more specific inhibitor and 
possibly reducing some side effects related to the contin-
uous use of anticoagulants such as heparin. Nevertheless, 
the fact that this inhibitor may acts directly against a specif-
ic coagulation factor could represent a bleeding risk factor. 
This fraction did not display cytotoxic effect on hemato-
poietic cells obtained from C57BL/6 mice at anticoagulant 
doses. Cellular viability was higher than that obtained with 
the control at some of tested concentrations. It could direct-
ly correlate to the increase in number of metabolic active 
cells. Those murine hematopoietic stem cells continue vi-
able after treatment at different concentrations of 1000RS 
and heparin. 
CONCLUSION 
The highest anticoagulant effect of 1000RS occurs at innoc-
uous doses, however, the anticoagulant effect and innocu-
ousness should be done using in vivo anticoagulant mod-
els and more accurate viability assays with normal human 
cell lines. This outcome is also promising when comparing 
1000RS with other bioactive polysaccharides such cellulose, 
starch sulfuric acid esters and chitin disulfuric acid, which 
have been shown to be considerably cytotoxic30.
Regarding the lack of activity on factor X or thrombin, it 
could be assumed that 1000RS does not interact with some 
serine protease inhibitors (serpins) such as antithrombin III 
(ATIII) and heparin cofactor II (HCII); regulatory plasmatic 
proteins which mainly inactivate these two serine proteases 
in plasma31. Once again, it supports the idea that the ascid-
ian polysaccharide fraction does not have the same mech-
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anism of action shared by several sulfated polysaccharides 
that, like heparin, has an anticoagulant action based on the 
potentiation of these natural inhibitors. This opens the pos-
sibility of having a new anticoagulant substance that can 
catalyze the allosteric change of other serpins like kallistatin 
(PI4), protein C inhibitor (PCI), Protein Z-dependent pro-
teinase inhibitor (ZPI), which can inhibit some homeostatic 
blood proteases of the intrinsic pathway like kallikrein, ac-
tive protein C and FXIa, respectively. It is also possible that 
it can act joining the protease with its respectively serpin 
through a “bridge” made of its glycosidic chain32,33.
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